Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
0.64
Facility
$72.81
Non-Facility
$72.81
Documentation Required
Results and interpretation of the specific surveillance test performed (NST tracings and accelerations/reactivity, BPP score components and total score, modified BPP results, Doppler indices such as pulsatility index (PI) or resistance index (RI) for umbilical artery, uterine artery, middle cerebral artery, MCA PSV numeric values and comparisons to reference ranges, documentation of absent/reversed end-diastolic flow if present).
Record of maternal self-assessment for fetal movement (kick counts) when used and any associated counseling/education provided.
For remote/home NST or telemonitoring: documentation of device used, dates/times of transmissions, transmitted FHR/NST tracings, clinician review/interpretation, and any follow-up actions (e.g., in-clinic evaluation required or avoided).
Key Coverage Criteria
Systemic lupus erythematosus (SLE) (M32.10 and O99.89 references)
Supervision of high-risk pregnancy (O09.00 - O09.93)
Proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium (O10.011 - O11.9, O12.10 - O16.9)
Hemorrhage in early pregnancy (O20.0 - O20.9)
Repeat testing (either weekly or twice‑weekly, depending on test and presence of certain high‑risk conditions) while the clinical condition that prompted testing persists.
Ask Verity about documentation requirements, denial risks, or coverage in your state.
Documentation that abnormal Doppler or surveillance findings are considered in conjunction with other tests of fetal well-being (e.g., amniotic fluid volume assessment, NST, CST, BPP) and maternal status when deciding timing of delivery or interventions.
For alloimmunization scenarios using MCA PSV: serial MCA PSV measurements, correlation with fetal anemia risk, and documentation of decisions regarding invasive testing or intrauterine transfusion based on findings.
If utilizing angiogenic biomarkers (sFlt-1, PlGF, sFlt-1/PlGF ratio) or novel Doppler measures (ophthalmic artery indices, uterine artery first-trimester screening), documentation of intended use (screening vs. diagnostic vs. research) and acknowledgment of current evidence/limitations and local practice guidelines.